UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2613-2622

2015

Volltextzugriff (PDF)

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression

Molecular cancer therapeutics, 2015-06, Vol.14 (6), p.1354-1364

2015

Volltextzugriff (PDF)

Sodium butyrate inhibits the self-renewal capacity of endometrial tumor side-population cells by inducing a DNA damage response

Molecular cancer therapeutics, 2011-08, Vol.10 (8), p.1430-1439

2011

Volltextzugriff (PDF)

Expression and silencing of the microtubule-associated protein Tau in breast cancer cells

Molecular cancer therapeutics, 2010-11, Vol.9 (11), p.2970-2981

2010

Volltextzugriff (PDF)

A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice

Molecular cancer therapeutics, 2016-06, Vol.15 (6), p.1163-1176

2016

Volltextzugriff (PDF)

Novel opportunities for thymidylate metabolism as a therapeutic target

Molecular cancer therapeutics, 2008-09, Vol.7 (9), p.3029-3037

2008

Volltextzugriff (PDF)

ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models

Molecular cancer therapeutics, 2014-05, Vol.13 (5), p.1345-1355

2014

Volltextzugriff (PDF)

Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A -Mutated Advanced Urothelial Carcinoma

Molecular cancer therapeutics, 2019-01, Vol.18 (1), p.185-195

2019

Volltextzugriff (PDF)

Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model

Molecular cancer therapeutics, 2020-06, Vol.19 (6), p.1320-1327

2020

Volltextzugriff (PDF)

Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy

Molecular cancer therapeutics, 2014-05, Vol.13 (5), p.1369-1381

2014

Volltextzugriff (PDF)

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

Molecular cancer therapeutics, 2016-07, Vol.15 (7), p.1669-1681

2016

Volltextzugriff (PDF)

Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody

Molecular cancer therapeutics, 2011-12, Vol.10 (12), p.2437-2448

2011

Volltextzugriff (PDF)

Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma

Molecular cancer therapeutics, 2015-10, Vol.14 (10), p.2238-2248

2015

Volltextzugriff (PDF)

The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias

Molecular cancer therapeutics, 2015-04, Vol.14 (4), p.889-898

2015

Volltextzugriff (PDF)

Met Signaling Cascade Is Amplified by the Recruitment of Phosphorylated Met to Lipid Rafts via CD24 and Leads to Drug Resistance in Endometrial Cancer Cell Lines

Molecular cancer therapeutics, 2015-10, Vol.14 (10), p.2353-2363

2015

Volltextzugriff (PDF)

The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy

Molecular cancer therapeutics, 2017-10, Vol.16 (10), p.2107-2119

2017

Volltextzugriff (PDF)

The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models

Molecular cancer therapeutics, 2012-08, Vol.11 (8), p.1799-1808

2012

Volltextzugriff (PDF)

Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells

Molecular cancer therapeutics, 2013-08, Vol.12 (8), p.1579-1590

2013

Volltextzugriff (PDF)

Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance

Molecular cancer therapeutics, 2014-06, Vol.13 (6), p.1578-1588

2014

Volltextzugriff (PDF)

Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity

Molecular cancer therapeutics, 2013-12, Vol.12 (12), p.2722-2734

2013

Volltextzugriff (PDF)

Longitudinal time-dependent effects of irradiation on multidrug resistance in a non-small lung cancer cell line

Molecular cancer therapeutics, 2014-11, Vol.13 (11), p.2706-2712

2014

Volltextzugriff (PDF)

Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity

Molecular cancer therapeutics, 2011-12, Vol.10 (12), p.2330-2339

2011

Volltextzugriff (PDF)

Imatinib and gastrointestinal stromal tumors: Where do we go from here?

Molecular cancer therapeutics, 2005-03, Vol.4 (3), p.495-501

2005

Volltextzugriff (PDF)

Role of the transcription factor Ets-1 in cisplatin resistance

Molecular cancer therapeutics, 2004-07, Vol.3 (7), p.823-832

2004

Volltextzugriff (PDF)

Cyclin A–associated kinase activity is needed for paclitaxel sensitivity

Molecular cancer therapeutics, 2005-07, Vol.4 (7), p.1039-1046

2005

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Zeitschrift / SerieMolecular Cancer Therapeutics

ThemaCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

Oncology
(29)
Humans
(28)
Life Sciences & Biomedicine
(26)
Science & Technology
(26)
Cell Line, Tumor
(20)
Animals
(16)
Drug Resistance, Neoplasm
(14)
Xenograft Model Antitumor Assays
(14)
Antineoplastic Agents - Pharmacology
(13)
Drug Resistance, Neoplasm - Genetics
(11)
Female
(11)
Mice
(11)
Cell Proliferation - Drug Effects
(6)
Drug Resistance, Neoplasm - Drug Effects
(6)
Gene Expression Regulation, Neoplastic
(6)
Cell Survival - Drug Effects
(5)
Indoles - Pharmacology
(5)
Mice, Nude
(5)
Phosphorylation
(5)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(29)
EZB Electronic Journals Library
(29)

Menü

Weitere Dienste

Einstellungen

Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression

Sodium butyrate inhibits the self-renewal capacity of endometrial tumor side-population cells by inducing a DNA damage response

Expression and silencing of the microtubule-associated protein Tau in breast cancer cells

A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice

Novel opportunities for thymidylate metabolism as a therapeutic target

ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models

Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A -Mutated Advanced Urothelial Carcinoma

Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model

Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody

Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma

The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias

Met Signaling Cascade Is Amplified by the Recruitment of Phosphorylated Met to Lipid Rafts via CD24 and Leads to Drug Resistance in Endometrial Cancer Cell Lines

The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy

The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models

Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells

Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance

Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity

Longitudinal time-dependent effects of irradiation on multidrug resistance in a non-small lung cancer cell line

Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity

Imatinib and gastrointestinal stromal tumors: Where do we go from here?

Role of the transcription factor Ets-1 in cisplatin resistance

Cyclin A–associated kinase activity is needed for paclitaxel sensitivity

Aktive Filter

Suchergebnisse filtern